scholarly journals Long-term Vaccine Impact on Invasive Pneumococcal Disease Among Children With Significant Comorbidities in a Large Australian Birth Cohort

2019 ◽  
Vol 38 (9) ◽  
pp. 967-973
Author(s):  
Sanjay Jayasinghe ◽  
Bette Liu ◽  
Heather Gidding ◽  
Amy Gibson ◽  
Clayton Chiu ◽  
...  
2017 ◽  
Vol 49 (5) ◽  
pp. 365-372 ◽  
Author(s):  
Hans Kristian Floeystad ◽  
Are Holm ◽  
Leiv Sandvik ◽  
Didrik Frimann Vestrheim ◽  
Bjorn Brandsaeter ◽  
...  

Author(s):  
Abelardo Claudio Fernández Chávez ◽  
Luis García Comas ◽  
Luis Manzano Espinosa ◽  
Jose Yuste Lobo ◽  
Octavio Corral Pazos de Provens ◽  
...  

AbstractThe major goals of the study were to describe the invasive pneumococcal disease (IPD) cases due to erythromycin-resistant serotypes and to evaluate the association between these cases and recent macrolide use in individuals aged over 59 years. We selected cases of IPD reported between 2007 and 2016 in persons aged over 59 years living in the Community of Madrid (CM). We followed the European Committee on Antimicrobial Susceptibility Testing (EUCAST). The explanatory variables (age, sex, year of onset of symptoms, clinical presentation, serotypes, vaccination status) were taken from the Mandatory Notification System for Infectious Diseases System and from the Vaccination Information System. The cases were classified as either included in the 13-valent pneumococcal conjugate vaccine (PCV13) or not (nonPCV13). Associations between cases due to erythromycin-resistant serotypes and previous macrolide use (total, long and short-term) were adjusted with a logistic regression multivariate analysis. A total of 1,831 cases were identified, of whom 408 were erythromycin-resistant serotypes. PCV13 cases were associated with previous macrolide use (OR: 5.07), particularly long-acting types (OR: 8.61). NonPCV13 cases were associated with the use of total macrolides (OR: 3.48) and long-acting macrolides (OR: 4.26) suggesting that PCV13 did not reduce the IPD cases in patients with previous use of macrolides. Our results confirmed that previous macrolide consumption was associated with the presence of IPD due to erythromycin-resistant serotypes. The risk was higher with the use of long-term macrolides.


Vaccine ◽  
2018 ◽  
Vol 36 (15) ◽  
pp. 1934-1940 ◽  
Author(s):  
Hanna Rinta-Kokko ◽  
Arto A. Palmu ◽  
Kari Auranen ◽  
J. Pekka Nuorti ◽  
Maija Toropainen ◽  
...  

2019 ◽  
Vol 70 (12) ◽  
pp. 2607-2615
Author(s):  
Kelley N Meder ◽  
Sanjay Jayasinghe ◽  
Frank Beard ◽  
Aditi Dey ◽  
Martyn Kirk ◽  
...  

Abstract Background Universal pneumococcal conjugate vaccine (PCV) programs began in Indigenous Australian children in 2001 and all children in 2005, changing to 13-valent PCV (PCV13) in 2011. We used laboratory data for invasive pneumococcal disease (IPD) and coded hospitalizations for noninvasive pneumococcal community-acquired pneumonia (PnCAP) to evaluate long-term impact. Methods Annual incidence (per 100 000 population) was calculated for age-specific total IPD, PCV13 non–7-valent PCV (PCV7) serotypes, and PnCAP by Indigenous status. Incidence in the pre–universal PCV7 (2002–2004), early PCV7 (2005–2007), pre-PCV13 (2008 to mid-2011), and post-PCV13 (mid-2011 to 2016) periods was used to calculate incidence rate ratios (IRRs). Results In the total population, all-age incidence of IPD declined from 11.8 pre-PCV7 to 7.1 post-PCV13 (IRR, 0.61 [95% confidence interval {CI}, .59–.63]) but for PnCAP declined among ages <1 year (IRR, 0.34 [95% CI, .25–.45]) and 1–4 years (IRR, 0.50 [95% CI, .43–.57]) but increased significantly among age ≥5 years (IRRs, 1.08–1.14). In Indigenous people, baseline PCV13 non-PCV7 IPD incidence was 3-fold higher, amplified by a serotype 1 epidemic in 2011. By 2015–2016, although incidence of IPD and PnCAP in children aged <5 years decreased by 38%, neither decreased in people aged ≥5 years. Conclusions Fifteen years post-PCV and 5 years post-PCV13, direct and indirect impact on IPD and PnCAP differed by age and between Indigenous and non-Indigenous people, with potential implications for long-term PCV impact in comparable settings. Fifteen years after pneumococcal conjugate vaccine (PCV) introduction and 5 years post-PCV13, direct and indirect impact on invasive pneumococcal disease and pneumococcal community-acquired pneumonia differed by age and between Indigenous and non-Indigenous people, with potential implications for long-term PCV impact in comparable settings.


2019 ◽  
Vol 188 (8) ◽  
pp. 1466-1474
Author(s):  
Anna Alari ◽  
Félix Cheysson ◽  
Lénaig Le Fouler ◽  
Philippe Lanotte ◽  
Emmanuelle Varon ◽  
...  

Abstract Geographic variations of invasive pneumococcal disease incidence and serotype distributions were observed after pneumococcal conjugate vaccine introduction at regional levels and among French administrative areas. The variations could be related to regional vaccine coverage (VC) variations that might have direct consequences for vaccination-policy impact on invasive pneumococcal disease, particularly pneumococcal meningitis (PM) incidence. We assessed vaccine impact from 2001 to 2016 in France by estimating the contribution of regional VC differences to variations of annual local PM incidence. Using a mixed-effect Poisson model, we showed that, despite some variations of VC among administrative areas, vaccine impact on vaccine-serotype PM was homogeneously confirmed among administrative areas. Compared with the prevaccine era, the cumulative VC impact on vaccine serotypes led, in 2016, to PM reductions ranging among regions from 87% (25th percentile) to 91% (75th percentile) for 7-valent pneumococcal conjugate vaccine serotypes and from 58% to 63% for the 6 additional 13-valent pneumococcal conjugate vaccine serotypes. Nonvaccine-serotype PM increases from the prevaccine era ranged among areas from 98% to 127%. By taking into account the cumulative impact of growing VC and VC differences, our analyses confirmed high vaccine impact on vaccine-serotype PM case rates and suggest that VC variations cannot explain PM administrative area differences.


2017 ◽  
Vol 13 (8) ◽  
pp. 1884-1891 ◽  
Author(s):  
Salaheddin M. Mahmud ◽  
Hasantha Sinnock ◽  
Luiz C. Mostaço-Guidolin ◽  
Gurpreet Pabla ◽  
Aleksandra K. Wierzbowski ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document